Pharmacological targeting of mRNA cap formation for treatment of parasitic infections
US6451583B1 · kind B1 · utility
1Cited by
0References
4Claims
0Family size
Inventors
Key dates
| Filing date | Dec 29, 2000 |
| Grant date | Sep 17, 2002 |
| Priority date | — |
| Expiry date | Dec 29, 2020 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
This invention provides the genes encoding the RNA triphosphatase and RNA guanylyltransferase of the malaria parasite Plasmodium falciparum and the catalytically active recombinant RNA triphosphatase and RNA guanylyltransferase enzymes. These enzymes form the basis of activity inhibition assays to identify molecules that specifically target the formation of the mRNA 5′ cap in unicellular eukaryotic parasites.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.